Item 8.01 Other Events

On January 28, 2020, Hepion Pharmaceuticals, Inc. (the "Company") issued a press release announcing positive findings from an expanded study with human precision cut liver slices. In this specialized experimental model using human liver tissue, the Company's drug candidate, CRV431, prevented experimentally induced liver fibrosis to a greater extent than four other leading NASH drug candidates: obeticholic acid ("OCA", an FXR agonist), elafibranor (a PPAR?/? agonist), resmetirom (a THR-? agonist), and Aramchol (an SCD1 inhibitor). A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits






(d) Exhibits



  99.1     Hepion Pharmaceuticals, Inc. Press Release dated January 28, 2020




                                       2

© Edgar Online, source Glimpses